GediCube Renovaro Biosciences NASDAQ; RENB
NASDAQ: $RENB
$RENB AI Healthcare
$RENB Strategic Companions
Revolutionizing Most cancers Detection: AI-Powered Diagnostics with Nvidia Tremendous Computing: Nasdaq: RENB
Renovaro Biosciences Inc (NASDAQ:RENB)
— Alessio Marcozzi, CSO of Cyclomics
LOS ANGELES, CALIFORNIA, UNITED STATES, April 25, 2024 /EINPresswire.com/ — Trailblazing AI-Pushed Early Most cancers Diagnostics and Therapeutics for Detection with Nvidia Tremendous Computing Energy; Buying 100% Possession of Cyclomics; Renovaro Inc. (Nasdaq: RENB)
$RENB is Working with $NVDA and Oxford Nanopore for Sequencing Expertise and Entrance Edge Software program Options
For extra data on this Thrilling NASDAQ Firm: RENB go to: http://www.renovarobio.com
Renovaro Inc (Nasdaq: RENB) goals to speed up precision and customized drugs for longevity powered by mutually reinforcing AI and biotechnology platforms for early prognosis, better-targeted remedies, and drug discovery. Renovaro consists of Renovaro Bio with its superior cell-gene immunotherapy firm and RenovaroCube. RenovaroCube has developed an award-winning AI platform that’s dedicated to the early detection of most cancers and its recurrence and monitoring subsequent remedies. RenovaroCube intervenes at a stage the place potential remedy will be only. RenovaroCube is a molecular knowledge science firm with a background in FinTech and a 10-year historical past. It brings collectively proprietary synthetic intelligence (AI) know-how, multi-omics, multi-modal knowledge, and the experience of a fastidiously chosen multidisciplinary workforce to radically speed up precision drugs and allow breakthrough modifications in most cancers care.
Upon the closing of the acquisition of Cyclomics (winner of the Well being Holland Enterprise Problem), RenovaroCube will probably be able to performing liquid biopsies utilizing proprietary applied sciences to establish single most cancers DNA molecules in just one vial of blood. Together with Oxford Nanopore Expertise, genetic data will be retrieved over a number of genetic layers to develop the following technology of most cancers diagnostics. This has the potential to remodel most cancers care by enabling quicker and extra correct prognosis all through the affected person journey.
RENB broadcasts a major milestone of their collaboration. RenovaroCube has entered into an modification to its binding letter of intent to amass 100% possession of Cyclomics, additional cementing their shared dedication to advancing state-of-the-art applied sciences in most cancers diagnostics and therapy. Their mixed relationships with Oxford Nanopore and Nvidia will additional place RenovaroCube to be a pacesetter in early most cancers diagnostics and monitoring of therapy efficacy. Oxford Nanopore is a pacesetter in sequencing applied sciences and Nvidia will present important supercomputing energy and front-edge software program options comparable to Parabricks, BioNeMo, Monai, and Nemo.
Initially set at a 75% acquisition, this resolution to amass the remaining 25% of Cyclomics displays the resounding success of their partnership and the exceptional synergy between the 2 firms. Upon closing, we consider the acquisition of Cyclomics into the Renovaro household will additional strengthen our capacity to create a powerhouse for most cancers diagnostics all through the whole affected person journey, from early detection/recurrence and customized therapy in late-stage illness
RENBs Mixed Firms goal to Disrupt Most cancers Analysis and therapy by way of early illness and recurrence detection, prediction of response to therapy, and customized remedy.
DISCLAIMER: https://corporateads.com/disclaimer/
All Disclosures listed on the www.corporateads.com
The Hon. Mark Dybul, MD, CEO
Renovaro Biosciences Inc
+1 732-780-5036
e mail us right here
Go to us on social media:
Twitter
LinkedIn
Nasdaq Interview with Dr. Mark Dybul, CEO of RENB
